Aarti PharmaQ3 FY24

Aarti Pharma Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,015.9P/E: 35.4Market Cap: ₹9.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Xanthine segment shows volume growth of around 3.5% YTD compared to last year, with expectations of 7-8% increase next fiscal due to debottlenecking initiatives.
  • CDMO & CMO segment anticipated to grow rapidly, with 40-50% growth expected next year and potential to make up 20-25% of total revenue in 2-3 years.
  • API and Intermediate segment expected to grow steadily, with a target of 15-20% revenue growth over next 2 years, despite pricing pressures.
  • Overall company EBITDA expected to grow 8-10% in FY24 and 12-17% annually over the next 2-3 years.
  • New product launches and increased customer base in CDMO and API segments to drive growth.
  • Greenfield expansion projects and capacity increases at Atali and Xanthine sites aimed at supporting long-term growth and enhanced volumes.

See what Aarti Pharma management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • The company plans to fund its upcoming CAPEX of around Rs. 100 crores over the next 2 years through a mix of internal accruals and borrowings.
  • Debt-equity ratio target is maintained between 0.3 and 0.35, indicating careful monitoring of leverage.
  • No explicit mention of equity fundraising in the current or near future.
  • The planned CAPEX totaling Rs. 400 to Rs. 500 crores over the next 12 to 18 months (including Atali expansion, solar projects, and Xanthine capacity) will also be funded via internal accruals and some borrowings.
  • The company is well-positioned in terms of debt-equities and business opportunities to support expansion without aggressive new fundraising.

See what Aarti Pharma management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Greenfield expansion project at Atali site: Rs. 375 crore CAPEX, targeted for completion in H2 FY25. This large manufacturing site will be developed in phases with multiple blocks, expanding capabilities including peptides and flow chemistry.
  • Xanthine primary raw material manufacturing project: Expected to start in Q4 FY24, reducing import dependency.
  • Semi-commercial production block at US FDA intermediate manufacturing site in Vapi: Aiming for completion in Q2 FY25.
  • Additional generic capacity expansion planned over next 15-18 months, with total CAPEX for 2024-25 estimated between Rs. 400 to Rs. 500 crore, including Rs. 90 crore for solar energy projects.
  • CAPEX funding mix: Internal accruals and borrowings while maintaining a target debt-equity ratio between 0.3 and 0.35.
  • Solar CAPEX (~Rs. 90 crore) will begin operating by H2 FY25, expected to reduce energy costs.

Track Aarti Pharma — get its next earnings analysis in your feed

How does Aarti Pharma rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisAarti Pharma
Rev 3Mar 3

How does Aarti Pharma rank in Pharmaceuticals & Biotechnology?

Compare Aarti Pharma against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →